Novel Soluble Guanylate Cyclase Activators For Pulmonary Artery Hypertension
Funder
National Health and Medical Research Council
Funding Amount
$474,087.00
Summary
Pulmonary hypertension (elevated blood pressure in the lungs) is a life-threatening condition with few treatment options. We have recently identified a new class of drug that may improve blood vessel function in the lungs and thereby provide a new drug for the management of this group of patients.
An Investigation Of The Involvement Of Clotting Factors In Abdominal Aortic Aneurysm (AAA) Progression Within A Mouse Model
Funder
National Health and Medical Research Council
Funding Amount
$189,401.00
Summary
Early stage weakening of the main abdominal artery is present in ~100,000 Australians and currently has no accepted therapy. Development of drug therapies which limit progression of the weakening process is urgently needed. In this study involvement of the clotting cascade in artery weakening will be investigated. The study have been planned in order to identify new strategies which can be developed as treatments for artery weakening in patients.
Development Of An Extended Release Oral Formulation Of Milrinone For Patients With Advanced Heart Failure
Funder
National Health and Medical Research Council
Funding Amount
$467,083.00
Summary
Heart failure is a debilitating condition associated with frequent hospitalization. Milrinone is an effective intravenous drug used to treat acute deteriorations. Previously, oral milrinone failed because of the lack of availability of appropriate formulations. We have developed an oral formulation which provides stable release of the medication. This application will evaluate the effectiveness of the drug in man and provide the documentation to take the project forward for partnership with indu ....Heart failure is a debilitating condition associated with frequent hospitalization. Milrinone is an effective intravenous drug used to treat acute deteriorations. Previously, oral milrinone failed because of the lack of availability of appropriate formulations. We have developed an oral formulation which provides stable release of the medication. This application will evaluate the effectiveness of the drug in man and provide the documentation to take the project forward for partnership with industry as a means to clinical translation.Read moreRead less
Ion channels are molecular pores of excitable membranes facilitating passage of ions and organic solutes across cellular membranes. An ever-increasing number of human and animal diseases result from malfunctioning ion channels making them to important therapeutic targets, which are modulated by a range of currently prescribed drugs. In the recent years the scientific and medical community has become increasingly aware of the role that mechanosensitive ion channels play in pathology of diseases i ....Ion channels are molecular pores of excitable membranes facilitating passage of ions and organic solutes across cellular membranes. An ever-increasing number of human and animal diseases result from malfunctioning ion channels making them to important therapeutic targets, which are modulated by a range of currently prescribed drugs. In the recent years the scientific and medical community has become increasingly aware of the role that mechanosensitive ion channels play in pathology of diseases including cardiac hyperthrophy and arrhythmias.Read moreRead less
Therapeutic Silencing Of Egr-1 By Novel Catalytic Oligodeoxynucleotides For The Treatment Of Acute Myocardial Infarction
Funder
National Health and Medical Research Council
Funding Amount
$384,353.00
Summary
Heart attack remains a major health problem. We have identified a gene in the heart which is turned on in the first few hours of a heart attack. We have shown in principle that switching this gene off using a novel synthetic drug, reduces heart attack size. Our project assesses the long term effects of this drug on the heart using state of the art imaging when the the drug is administered in a clinically relevant manner. This study may faciliate a new treatment approach for this condition.
Mechanisms Underlying The Contribution Of Uremic Toxins To Cardiorenal Syndrome
Funder
National Health and Medical Research Council
Funding Amount
$413,533.00
Summary
Cardiorenal syndrome (CRS) is an umbrella term that defines disorders of the heart and kidneys whereby “acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other”. We have demonstrated a significant association between heart and kidney fibrosis (scarring) and levels of a uremic toxin called indoxyl sulphate (IS), in relevant animal models and that blockade of production of this toxin reduces cardiac fibrosis. This project aims to explore this association.
Novel Therapy For Heart Failure With Preserved Ejection Fraction
Funder
National Health and Medical Research Council
Funding Amount
$1,068,984.00
Summary
Heart failure is a major cardiovascular problem. Up to half of the patients have a specific problem with heart muscle relaxation. There is no effective therapy for this type of heart failure. We will investigate the effects of new treatment approach using a range of experimental and clinical methods. If successful the treatment could move quickly into clinical practice.
Heart failure (HF) describes where the heart cannot pump adequately to meet the bodyÍs needs. Mortality remains high; therefore, there is an urgent need for new treatment approaches. The present grant aims to: (1) evaluate treatments for patients at high-risk for future development of HF (2) examine the ability to safely withdraw unnecessary HF drugs (3) focus on the effect of HF on the kidney via novel treatment strategies (4) examine the emerging role of cancer drugs in development of HF.
DEFINING NONCLASSICAL ANGIOTENSIN SIGNALLING AND CARDIOVASCULAR FUNCTION
Funder
National Health and Medical Research Council
Funding Amount
$634,580.00
Summary
Angiotensin II is a hormone which is well known to contribute to high blood pressure and cardiovascular disease. This proposal will use highly novel compounds that we have synthesised that, for the first time, selectively target nonclassical angiotensin-related binding sites, so called NON-AT1 receptors, which are thought to counteract the deleterious effects of angiotensin II that normally causes fibrosis or scarring of the heart which damages healthy muscle.
A Study Of The Plaque-modifying Actions Of Colchicine In Stable And Unstable Atherosclerosis: From Mouse Models To Clinical Imaging.
Funder
National Health and Medical Research Council
Funding Amount
$1,198,460.00
Summary
Inflammation causes the plaques in arteries that cause heart attacks and strokes. There is major interest in developing drugs that reduce this inflammation for patients with heart disease. We are studying the effects of colchicine, an anti-inflammatory drug used to treat the joint disease, gout, in order to see whether it also prevents the build up of plaques and their progression to heart attacks and strokes.